On April 28, 2026, Dalian Bio-Chem Company Limited (referred to as Dalian Bio-Chem, stock code: 603360) announced that it had received a notice of case filing from the China Securities Regulatory Commission (CSRC). The announcement stated that due to the company's suspected violations of information disclosure regulations and other related laws, the CSRC has decided to initiate an investigation into the company in accordance with the provisions of the Securities Law of the People's Republic of China.
On the same day, Dalian Bio-Chem also released an announcement regarding the "Correction of Prior Period Accounting Errors and Retrospective Adjustments to Financial Statements and Related Notes." The company's board of directors reviewed and approved the proposal concerning the correction of prior period accounting errors and retrospective adjustments. The company agreed to correct the prior period accounting errors and make retrospective adjustments to the financial statement items and related notes in the 2024 Annual Report, the 2025 First Quarter Report, the 2025 Semi-Annual Report, and the 2025 Third Quarter Report, in accordance with relevant regulations and requirements, including Accounting Standards for Business Enterprises No. 28—Changes in Accounting Policies and Estimates, and Corrections of Errors, and the Rules for the Compilation and Disclosure of Information of Companies Offering Securities to the Public No. 19—Correction of Financial Information and Related Disclosure.
According to the Civil Code, the Securities Law, and the judicial interpretations issued by the Supreme People's Court concerning civil compensation for misrepresentation, listed companies, controlling shareholders, actual controllers, directors, supervisors, senior management personnel, and their intermediaries who engage in securities fraud such as misrepresentation, resulting in damage to the rights and interests of securities investors, shall bear civil liability for compensation. The scope of compensation includes investment loss differentials, commissions, stamp duties, and other related losses. Securities investors whose rights and interests have been damaged may file civil compensation lawsuits with courts having jurisdiction.
As Dalian Bio-Chem is suspected of violating information disclosure regulations and is under investigation by the CSRC, in order to protect the legitimate rights and interests of securities investors, lawyer Song Yixin from Shanghai Hanlian Law Firm is initiating a collection of litigation representation for securities investors who have previously purchased Dalian Bio-Chem securities. The lawyer will represent investors in compensation claim lawsuits. Investors who have suffered damages to their rights and interests can register their claims with the aforementioned lawyer.
Lawyer Song Yixin believes that the eligibility criteria for claims in the Dalian Bio-Chem case are as follows: investors who purchased publicly offered securities products such as Dalian Bio-Chem stocks or bonds between April 25, 2025, and April 27, 2026, and sold or continued to hold these securities on or after April 28, 2026, and suffered losses, are eligible to register for compensation claims.
Notes and Clarifications from the Lawyer Regarding This Case:
1. The aforementioned claim eligibility criteria are for reference only and do not constitute any investment decision or securities trading advice for investors. The final claim conditions will be further adjusted based on the conclusions of the CSRC's administrative penalty decision and will be subject to the legal time points, compensation targets, compensation scope, compensation standards, and accounting calculation methods determined by the final effective judgment of the relevant court.
2. Although investors can file lawsuits directly after the removal of the precondition requiring an administrative penalty decision, due to limited investigation methods, filing a lawsuit based solely on the notice of case filing or administrative regulatory measures decision carries a risk of losing the case. Therefore, as a professional lawyer, I advise investors that an administrative penalty decision should still be considered a necessary prerequisite for filing a lawsuit.
3. In intended civil tort litigation cases, whether the listed company is delisted or not does not affect the progress of the civil compensation tort litigation, but it may impact the pace of the litigation. However, entering bankruptcy proceedings (including reorganization, pre-reorganization, or liquidation) may significantly affect the litigation timeline. If a representative action occurs, you may choose to participate or not, join or withdraw.
4. Investors registering or pre-registering for compensation claims should provide the following materials: (1) A copy of their ID card. (2) The original "Securities Account Opening Information Confirmation Form" for various securities accounts, including the unified account, stamped with the seal of the securities company's business department. (3) The original "Securities Transaction History Statement" from the first purchase of the stock/bond/warrant, etc., to the present, stamped with the seal of the securities company's business department.
Introduction to Lawyer Song Yixin: Having practiced law since 1992, he is currently a partner at Shanghai Hanlian Law Firm. His service areas primarily include legal services for capital markets, securities markets, financial markets, and the protection of investor/financial consumer rights and interests. Since beginning his practice, he has provided legal services for over 10,000 securities litigation matters or shareholder dispute matters. He has authored and compiled books such as "Securities Law Principles and Practice," "Securities Civil Compensation Practice Manual," "Stock Market Rights Protection," "Compilation of Judicial Judgment Documents for Securities Civil Compensation Cases in China," and "Directors' Liability Insurance and Investor Rights Protection."
Comments